CYTK — CYTOKINETICS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1061983 ·
Last close
$64.66
Market Cap
$8.99B
52W High
$88.31
52W Low
$47.87
ADV30
1,888,603
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 28,624,000 | 23,032,000 | -179,172,000 | -198,762,000 | 1,924,551,000 | 255,271,000 | 2,098,038,000 |
| Mar 2026 | 19,355,000 | 16,803,000 | -183,618,000 | -206,031,000 | 1,273,478,000 | 129,843,000 | 2,100,046,000 |
| Dec 2025 | 17,755,000 | -86,643,000 | -178,366,000 | -183,031,000 | 1,424,537,000 | 122,518,000 | 2,084,162,000 |
| Sep 2025 | 1,936,000 | -97,297,000 | -166,755,000 | -306,178,000 | 1,436,557,000 | 225,467,000 | 1,957,680,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-523,849,000
Investing CF
$56,202,000
Financing CF
$527,474,000
CapEx
$-25,073,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.84
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,891,512,000
Inventory
$380,000
Receivables
$24,432,000
ST Investments
$910,415,000
EBIT TTM
$-769,179,000
Pretax Income TTM
$-894,002,000
Interest Exp TTM
$124,823,000
Analysts
20
Yahoo Snapshot (yfinance, live)
Total Revenue
$67,670,000
EBITDA
$-695,361,984
Free Cash Flow
$-397,408,736
Enterprise Value
$10,514,526,208
Total Cash
$1,165,686,016
Total Debt
$1,424,455,040
Shares Out
139,023,418
Trailing EPS
$-7.22
Book Value
$-1.25
ROE
—
ROA
-28.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 88,039,000 | -612,258,000 | -784,955,000 | 1,424,537,000 | 2,084,162,000 | -659,625,000 | -510,009,000 |
| Dec 2024 | 18,474,000 | -536,248,000 | -589,526,000 | 1,401,673,000 | 1,537,045,000 | -135,372,000 | -395,890,000 |
| Dec 2023 | 7,530,000 | -496,205,000 | -526,244,000 | 824,316,000 | 1,210,639,000 | -386,323,000 | -414,333,000 |
| Dec 2022 | 94,588,000 | -324,202,000 | -388,955,000 | 1,014,775,000 | 1,122,675,000 | -107,900,000 | -299,516,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.45
Max Pain — expiry 2027-01-15
max pain strike: $40.00 · spot: $64.64 · call oi: 38,585 · put oi: 2,900
Expected Move to 2027-01-15:
±$14.75
(22.82%) —
implied range
$49.89 –
$79.39
· ATM straddle on $65.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc | $9.18B | $141.86 | — |
| TGTX | TG THERAPEUTICS, INC. | $8.79B | $57.43 | — |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $9.31B | $65.92 | — |
| ABVX | Abivax S.A. | $7.95B | $91.06 | — |
| RDY | DR REDDYS LABORATORIES LTD | $10.20B | $12.25 | — |
News headlines (Yahoo Finance, 1h cache)
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference
2026-09-25 14:02 · Yahoo
Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story?
2026-09-23 13:21 · Yahoo
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-17 20:00 · Yahoo
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
2026-09-14 11:30 · Yahoo
Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says
2026-09-10 16:08 · Yahoo
Could Aficamten Give Cytokinetics the First Approved nHCM Treatment?
2026-09-08 01:05 · Yahoo
Cytokinetics to Participate in September Investor Conferences
2026-09-02 20:00 · Yahoo
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
2026-09-02 18:30 · Yahoo
Cytokinetics (CYTK) Presents New Phase 3 Data, Is It Still 34% Undervalued?
2026-09-01 13:08 · Yahoo
Cytokinetics (CYTK) Reaches A Phase 3 First In Non Obstructive HCM
2026-09-01 05:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.